ARID2 Antibody
Description
Applications of ARID2 Antibodies
ARID2 antibodies are utilized in diverse experimental workflows:
ARID2 as a Tumor Suppressor
-
HCC Metastasis: ARID2 loss correlates with poor prognosis and enhanced epithelial-mesenchymal transition (EMT). Antibody-based assays confirmed reduced ARID2 in metastatic HCC tissues compared to adjacent normal liver .
-
Mechanism: ARID2 recruits DNMT1 to methylate the Snail promoter, suppressing EMT. C2H2 domain truncations (e.g., 3817C>T) disrupt this interaction, promoting metastasis .
DNA Repair and Therapy Response
-
ARID2-deficient lung cancer cells show impaired DNA repair and increased sensitivity to cisplatin and PARP inhibitors . Antibodies validated ARID2 protein loss in 20% of lung cancer patients .
Cell Cycle Regulation
-
ARID2 suppresses cyclin D1 and E1 expression via the Rb-E2F pathway, inhibiting hepatoma cell proliferation. Antibodies demonstrated ARID2 downregulation in HCC tumors .
Technical Considerations
-
Validation: Knockout/knockdown models (e.g., Arid2−/− mice) and siRNA transfection confirm antibody specificity .
-
Epitope Mapping: Most antibodies target the C-terminal region (e.g., aa 1750–1835), critical for chromatin remodeling .
Clinical Implications
ARID2 antibodies are pivotal in:
Product Specs
**Constituents:** 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
Q&A
Basic Research Questions
How to select and validate ARID2 antibodies for chromatin remodeling studies?
Key validation steps include:
-
Epitope specificity: Use siRNA/shRNA knockdown controls in Western blot (e.g., A549/H460 lung cancer cells showing ≥70% ARID2 reduction after shRNA treatment ).
-
Cross-reactivity testing: Validate against related SWI/SNF complex proteins (e.g., ARID1A/ARID1B) using lysates from ARID2-deficient cell lines .
-
Functional correlation: Compare immunohistochemistry (IHC) results with mRNA quantification (qRT-PCR) in matched clinical samples, as demonstrated in HCC studies where ARID2 IHC scores inversely correlated with Snail promoter methylation .
How to resolve contradictory findings about ARID2's role in cancer progression?
Experimental design considerations:
| Observation | Context | Mechanism | Citation |
|---|---|---|---|
| Pro-metastatic | Lung cancer | ARID2 loss → impaired DNA repair → genomic instability | |
| Anti-metastatic | HCC | ARID2 recruits DNMT1 → Snail suppression |
-
Tissue-specific analysis: Perform organotypic 3D culture models with CRISPR-edited ARID2 clones
-
Pathway mapping: Combine ChIP-seq (ARID2/DNMT1 binding) with whole-exome sequencing in isogenic cell pairs
How to standardize ARID2 quantification across platforms?
Inter-assay comparison data:
What controls are essential for ARID2 functional studies?
-
Negative: ARID2 C2H2 domain mutants (e.g., 3817C>T) in invasion assays
-
Dosage controls: Tetracycline-inducible shRNA systems (1 µg/ml doxycycline)
Clinical Correlation Data
ARID2 Expression vs HCC Patient Survival
| ARID2 Level | 5-Year Survival | Metastasis Rate |
|---|---|---|
| High (H-score ≥50) | 68% | 12% |
| Low (H-score <50) | 29% | 47% |
